Skip to content

Advertisement

  • Oral presentation
  • Open Access

Parallel dysregulation across psychoimmunological and cardiovascular response systems in HIV+ outpatients

  • 1, 2Email author,
  • 1,
  • 1 and
  • 1
Retrovirology20063 (Suppl 1) :S74

https://doi.org/10.1186/1742-4690-3-S1-S74

  • Published:

Keywords

  • Multiple Regression Analysis
  • Recovery Period
  • Cardiovascular Response
  • High Type
  • Central Hypothesis

Background

Higher Type C coping (under-recognition and under-expression of stress/needs/emotion, and psychological/psychophysiological dyssynchrony) is associated with faster HIV progression. In a pilot study, we found that higher Type C coping was significantly associated with lower HIV-specific antigen-stimulated production of HIV CCR5 co-receptor ligands (beta-chemokines MIP-1α/β), which are potent HIV inhibitors. This study replicates and extends these findings.

Methods

Type C coping was assessed using the validated Vignette Similarity Coping Method. In-vitro production of MIP-1α/β in response to the HIV-specific p24 antigen was measured by ELISA from supernatants collected on days 3 and 6. Heart rate and systolic/diastolic blood pressure were recorded every 90 seconds during two emotion-induction tasks, each preceded by a baseline resting period and followed by a recovery period.

Results

Results from the first 100 participants (90% African-American, 55% female) suggest a replication of our previous finding: strong Type C coping is associated with significantly decreased MIP-1α production (r = -1.81, p = .04). In multiple regression analyses adjusted for age and medication use, greater HR reactivity/poorer HR recovery to baseline are significantly associated with decreased MIP-1α/β response to the p24 antigen.

Conclusion

These findings support our central hypothesis that dysregulated coping and physiological patterns are associated with HIV immune responses that contribute to HIV progression.

Authors’ Affiliations

(1)
Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
(2)
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA

Copyright

Advertisement